What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk ( NYSE:NVO )
36.8% on Wegovy showed liver fibrosis improvement vs 22.4% on placebo at week 72. FDA approval adds MASH with liver fibrosis to Wegovy's indications. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. On Saturday, the U.S.
Billionaire Investor Buys Google And This Gold Miner Stock - Perpetua Resources ( NASDAQ:PPTA )
John Paulson's hedge fund, Paulson & Co., discloses the purchase of 9,000 shares of Alphabet. The also increases its position in gold miner Perpetua Resources. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal ( MDGL ) Q2 Revenue Soars 1,313%
Madrigal Pharmaceuticals ( NASDAQ:MDGL ) , a biopharmaceutical firm focused on liver diseases, reported its second quarter 2025 earnings on August 5, 2025. The standout news in this release was an explosive surge in GAAP revenue to $212.8 million, sharply exceeding the consensus estimate of ...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Second-quarter 2025 Rezdiffra™ ( resmetirom ) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP-1 development candidate
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports second-quarter 2025 financial results and ...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
CONSHOHOCKEN, Pa., July 30, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) ( "Madrigal" ) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited ( HKEX Stock CodeL 1093 ) ( "CSPC" ) for SYH2086, a ...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
CONSHOHOCKEN, Pa., July 25, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , announced today that it will release its second-quarter ...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., July 25, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
CONSHOHOCKEN, Pa., July 22, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it has entered into a $500 million ...
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Madrigal's Fatty Liver Disease Drug Gets Recommendation - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CHMP recommends conditional EU approval of Rezdiffra for noncirrhotic MASH with fibrosis. Two-year data show 51% of patients had ≥25% improvement in liver stiffness. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
Madrigal Receives Positive CHMP Opinion for Resmetirom ( Rezdiffra™ ) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., June 20, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that the Committee for Medicinal Products ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., June 17, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., June 02, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - Aardvark Therapeutics ( NASDAQ:AARD )
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
SAN DIEGO, May 19, 2025 ( GLOBE NEWSWIRE ) -- Aardvark Therapeutics, Inc. ( Aardvark ) ( Nasdaq: AARD ) , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today ...
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.Recognizing those corporations with long-term ...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis ...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Late-breaking results from the open-label compensated MASH cirrhosis ( F4c ) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension ( CSPH ) at baseline moved into lower risk categories by year two
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., May 10, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced positive two-year results from the ...
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 01, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports first-quarter 2025 financial results and ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
CONSHOHOCKEN, Pa., April 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , announced today that it will release its first-quarter ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., April 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture? - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals MDGL, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday - ASP Isotopes ( NASDAQ:ASPI ) , ACM Research ( NASDAQ:ACMR )
U.S. stocks were mixed, with the Dow Jones falling over 150 points on Wednesday. Shares of Workday, Inc. WDAY rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter financial results.
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Rezdiffra reduced liver stiffness by 6.7 kPa at two years, with 51% of patients showing ≥25% improvement in MASH cirrhosis. Madrigal posted a Q4 loss of $2.71 per share, beating estimates, with sales of $103.22 million surpassing the $98.56 million consensus.
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals ( NASDAQ: MDGL ) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of ...
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ ( resmetirom ) in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reported positive two-year results from the ...
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
CONSHOHOCKEN, Pa., Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( Nasdaq: MDGL ) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
CONSHOHOCKEN, Pa., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( Nasdaq: MDGL ) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics ( NASDAQ: AKRO ) is part of this group. On Jan. 27, the company's shares soared by 97%, closing the day at $51.71.
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals ( NASDAQ: MDGL ) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had ...
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Shares of Madrigal Pharmaceuticals ( NASDAQ: MDGL ) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full-year 2024 results. Madrigal reported preliminary Q4 net sales for its metabolic steatohepatitis ( ...
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
CONSHOHOCKEN, Pa., Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced an update on its business performance, ...
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( Nasdaq: MDGL ) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be ...
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Viking Therapeutics ( NASDAQ: VKTX ) is a hot biotech stock thanks to the company's record of reporting good data from its cardiometabolic disease programs, and there's no sign of that reputation being tarnished.In fact, Viking just gave investors an update which firms up its status as a very ...
Top 3 Health Care Stocks That May Dip This Month - Conmed ( NYSE:CNMD ) , Butterfly Network ( NYSE:BFLY )
As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics ( NASDAQ: VKTX ) .
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals ( NASDAQ: MDGL ) . Earlier this year, the up-and-coming biotech received approval of a pioneering ...
Madrigal ( MDGL ) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
The plunge in Viking Therapeutics' share price can be attributed to the rising competition in the sector to secure a position in the booming obesity market.
